{"id":"ultrix-inactivated-split-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the introduction of inactivated split influenza virus antigens, which trigger the body's immune system to produce antibodies and immune cells that can recognize and fight the virus.","oneSentence":"Ultrix stimulates an immune response against the influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:27.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza disease caused by influenza A and B viruses in individuals 6 months of age and older."}]},"trialDetails":[{"nctId":"NCT05869201","phase":"PHASE2, PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-10-06","conditions":"Influenza, Influenza, Human, Influenza Viral Infections","enrollment":450},{"nctId":"NCT05308212","phase":"PHASE2, PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2021-03-04","conditions":"Influenza","enrollment":633},{"nctId":"NCT05457894","phase":"PHASE3","title":"Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-01-23","conditions":"Influenza, Human, Vaccination; Infection, Vaccines","enrollment":207},{"nctId":"NCT05317767","phase":"PHASE3","title":"The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-02-10","conditions":"Influenza","enrollment":600},{"nctId":"NCT05089123","phase":"PHASE3","title":"The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-03-03","conditions":"Influenza","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ultrix®, Inactivated Split Influenza Vaccine","genericName":"Ultrix®, Inactivated Split Influenza Vaccine","companyName":"St. Petersburg Research Institute of Vaccines and Sera","companyId":"st-petersburg-research-institute-of-vaccines-and-sera","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ultrix stimulates an immune response against the influenza virus. Used for Prevention of influenza disease caused by influenza A and B viruses in individuals 6 months of age and older..","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}